Transactions of Managers and Closely Associated Persons
Rhea-AI Summary
Alvotech (ALVO) disclosed two manager/closely associated person transactions recorded in filings with the Luxembourg CSSF. ATP Holdings ehf acquired 4,812,257 shares on December 17, 2025 and 2,110,640 shares on December 19, 2025 at a transaction price of SEK 44.06 per share, for a combined total of 6,922,897 shares. The disclosures are attached and list investor relations contact Benedikt Stefansson.
Positive
- Insider purchases: 6,922,897 shares acquired
- Transaction price: SEK 44.06 per share
- Two CSSF filings cover Dec 17 and Dec 19, 2025 transactions
Negative
- None.
News Market Reaction
On the day this news was published, ALVO declined 6.53%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.1% during that session. Argus tracked a trough of -6.0% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $102M from the company's valuation, bringing the market cap to $1.46B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALVO was down 2.0% while key peers showed mixed modest moves, from -2.41% (HCM) to +2.52% (INDV), suggesting stock-specific dynamics rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 31 | Debt financing | Positive | -2.5% | Secured USD 100M senior term loan facility to bolster liquidity and launches. |
| Dec 29 | Share structure update | Neutral | -5.5% | Notification to CSSF regarding changes in the company’s own shares. |
| Dec 22 | Financial calendar | Neutral | +0.8% | Published 2026 schedule for results, investor calls and annual meeting. |
| Dec 22 | Product launch | Positive | +0.8% | European launch of first-in-market Simponi biosimilar Gobivaz with Advanz. |
| Dec 19 | Settlement/license | Positive | +3.6% | Settlement with Regeneron granting U.S. AVT06 market entry timing. |
Recent news flow mixes financing, regulatory approvals and partnerships, with positive product or settlement updates often aligning with upward moves, while financing and share-structure items have coincided with pressure.
Over the past few months, Alvotech reported multiple milestones, including a USD 100 million senior term loan maturing in December 2027, European launches of Gobivaz, and a U.S. settlement enabling AVT06 entry as early as Q4 2026. It also communicated changes in its own shares and published a 2026 financial calendar. Positive commercial and settlement news generally aligned with gains, while financing and share-related disclosures coincided with negative moves. The latest disclosure of large share acquisitions by ATP Holdings fits into this pattern of capital and ownership-related updates.
Market Pulse Summary
The stock moved -6.5% in the session following this news. A negative reaction despite disclosed share acquisitions by ATP Holdings, totaling over 6.9 million shares at SEK 44.06, would fit a pattern where financing and share-structure headlines sometimes coincided with weakness. Earlier term-loan and own-share notifications were followed by declines, suggesting sensitivity to capital and ownership changes. Such responses could reflect ongoing concerns captured by the stock’s position below its $8.15 200-day moving average.
Key Terms
CSSF regulatory
AI-generated analysis. Not financial advice.
Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of shares in Alvotech by ATP Holdings ehf. The shares were aquired in two transactions, 4,812,257 shares on December 17, 2025 and 2,110,640 shares on December 19, 2025. The transaction price was SEK 44.06 per share.
ALVOTECH INVESTOR RELATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
Attachments
FAQ
Who bought Alvotech (ALVO) shares in December 2025?
How many Alvotech (ALVO) shares did ATP Holdings ehf acquire in total?
What price per share was paid for ALVO transactions on Dec 17 and Dec 19, 2025?
When were the Alvotech (ALVO) transactions reported to the CSSF?
What were the individual share amounts for the ALVO transactions on Dec 17 and Dec 19, 2025?
Who is the investor relations contact for Alvotech regarding these filings?
